Sep 21, 2015
Cadwalader is pleased to announce it represented Credit Suisse in a transaction for which Credit Suisse was the sole structuring and financial advisor to AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) in the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil sublingual tablet system) in the European Union by its commercial partner Grunenthal GmbH. AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that gross proceeds from the sale are $65 million.
The Cadwalader team included Christopher Cox, Corporate; Ira Schacter and Steve Lenkowsky, Capital Markets; Dorothy Auth, Intellectual Property; and David Miller, Tax.
Pro Bono Report 2019